4/24/2009

Biotech firm Sanaria and the Path Malaria Vaccine Initiative are preparing to launch the first human trials of a vaccine that contains a weakened version of an entire malaria parasite found in radiation-zapped mosquitoes. The groups plan to enroll 104 healthy volunteers and expect to treat the first patient in mid-May.

Related Summaries